TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02546726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat & Aerobic Training (HEAT)
Description: Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Only
Description: Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
Study: NCT03958318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise plus nutritional suplementation
Description: For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
Study: NCT05250921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: Corticision will be performed to enhance teeth alignment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fixed appliance
Description: No surgical intervention is going to be applied to the patients in this group.
Study: NCT00325507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax
Description: TroVax 1 x 10E9 TCID 50mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6
Study: NCT03411018

Intervention type: OTHER
Intervention: Mechanical ventilation exposure

Intervention type: OTHER
Intervention: Mechanical ventilation exposure
Study: NCT00153673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: Celecoxib 200mg bd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dologesics
Description: Dologesics 2 tablets bd
Study: NCT01122446

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo.
Study: NCT03958318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
Study: NCT01122446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamyd
Description: 20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd
Study: NCT00794846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg (Clarinex)
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine (Zyrtec)
Description: Zyrtec 10 mg daily x 7 days
Study: NCT01369199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir and peginterferon
Description: Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
Study: NCT00955474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m.
Study: NCT01766219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study: NCT00690417

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
Study: NCT00955474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.
Study: NCT01279876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 3mg oral, daily, one hour before sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: 3mg oral, daily, one hour before sleep
Study: NCT04970173

Intervention type: OTHER
Intervention: use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy
Description: Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.

Intervention type: OTHER
Intervention: use of a very low-volume 1L-PEG plus ascorbate (plenvu) or low-volume 2L-PEG plus ascorbate (moviprep) for bowel preparation in open access colonoscopy
Description: Patients are free to choice the kind of BP in an open access booking system colonoscopy. The safety of BPs was assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of the five Hospitals of our Digestive Endoscopy Unit in the 7 days following the colonoscopy. This was feasible since the electronic reporting system is the same across our five Hospitals.
Study: NCT01999686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Study: NCT02054130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929 280 mg
Description: Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Study: NCT00690417

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: low calorie (\~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
Study: NCT03848715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin
Study: NCT01551641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without thalidomide
Description: Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
Study: NCT00784186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone+misoprostol
Description: single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
Study: NCT03848715

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04580160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duo Venous Stent System
Description: Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.
Study: NCT01999686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metformin
Description: Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DLBS3233
Description: Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
Study: NCT02578446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncemented Triathlon Tritanium CR Total Knee System
Description: Primary Total Knee Replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Triathlon CR Total Knee System
Description: Primary Total Knee Replacement
Study: NCT02778945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Description: Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Description: Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
Study: NCT00640276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pitavastatin
Description: Pitavastatin 2mg daily once

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Modification
Description: conducting mainly exercises and diet
Study: NCT00784186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study: NCT02564419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+S
Description: Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
Study: NCT02856880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test zinc-IPMP toothpaste
Description: Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test zinc non- IPMP toothpaste
Description: Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SLS negative control
Description: Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-SLS negative control
Description: Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
Study: NCT00937378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER120
Description: Nasal Spray, once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray
Study: NCT01281189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral tablet 150mg twice daily for up to 18 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet twice daily for up to 18 months.
Study: NCT02823860

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of biospecimens and Quality of Life (QoL) assessment
Description: Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
Study: NCT03113513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the vaginal apex
Description: In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the vaginal apex
Description: In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
Study: NCT02671227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal Mg sulfate.
Description: intrathecal Mg sulfate 50 mg.
Study: NCT01563107

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Plasma Volume
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Plasma Volume
Description: Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Capacity Test - Bicycle
Description: subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Capacity Test - Bicycle
Description: subjects breathe room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture Study
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posture Study
Description: Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
Study: NCT01320956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre operative nurse consultation and Hypnosis
Description: Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre operative nurse consultation
Description: Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
Study: NCT02204813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lo-Xenin
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hi-Xenin
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extra Hi-Xenin
Description: A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours.
Study: NCT03380338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength exercise
Study: NCT02414971

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT01165697

Intervention type: OTHER
Intervention: Fluorescein angiography
Description: Fluorescein angiography once every 6 months for 3 years
Study: NCT02197897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Single-center, two-stage phase-II clinical trial (Simon design)
Study: NCT02693327

Intervention type: OTHER
Intervention: Biological Sample
Description: A one time sample will be collected.

Intervention type: OTHER
Intervention: Biological Sample
Description: A one time sample will be collected.

Intervention type: OTHER
Intervention: Blood Sample
Description: A one time blood sample will be collected.

Intervention type: OTHER
Intervention: Blood Sample
Description: A one time blood sample will be collected.
Study: NCT02074943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP will be inject to half head. The other half will be injected with normal saline.
Study: NCT02593903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Septra
Study: NCT02467023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Biopsy Medication: Versed
Description: Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy Medication: Fentanyl
Description: Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
Study: NCT01412515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus per os 10mg per day
Study: NCT03768089

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-121 suspension)
Description: Placebo matched to VX-121 suspension for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to VX-121 suspension)
Description: Placebo matched to VX-121 suspension for oral administration.